Help
RSS
API
Feed
Maltego
Contact
Domain > ir.avalotx.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-10-06
3.221.176.71
(
ClassC
)
2022-02-17
3.225.74.242
(
ClassC
)
2026-01-04
54.183.47.117
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Sun, 04 Jan 2026 11:40:27 GMTServer: ApacheStrict-Transport-Security: max-age31536000; includeSubDomains; preloadX-Frame-Options: SAMEORIGINX-XSS-Protection: 1; modeblockX-Content-Type-Options: nosniffPermissions-Policy: microphone(), camera(), geolocation(), screen-wake-lock()Referrer-Policy: strict-origin-when-cross-originContent-Security-Policy: script-src nonce-wgyGjXxYUGADTf3aVhTZag www.googletagmanager.com qmod.quotemedia.com self *.cloudfront.net website-search.ent.us-east-1.aws.found.io; style-src static.c1.quotemedia.com qmod.quotemedia.com cdnjs.cloudflare.com self *.cloudfront.net fonts.googleapis.com shared.equisolve.net unsafe-inline *.wpenginepowered.com; font-src static.c1.quotemedia.com self *.cloudfront.net cdnjs.cloudflare.com/ajax/libs/font-awesome/ fonts.googleapis.com data: *.wpenginepowered.com; default-src www.google-analytics.com qmod.quotemedia.com app.quotemedia.com influxdb.quotemedia.com static.c1.quotemedia.com cdnjs.cloudflare.com self *.cloudfront.net website-search.ent.us-east-1.aws.found.io *.wpenginepowered.com; img-src qmod.quotemedia.com self *.cloudfront.net shared.equisolve.net *.wpenginepowered.com *.globenewswire.com; media-src self *.cloudfront.net shared.equisolve.net; frame-ancestors selfVary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8 !DOCTYPE html>html langen>head> meta http-equivx-ua-compatible contentieedge> meta charsetutf-8> link relalternate typeapplication/rss+xml titleAvalo Therapeutics, Inc. - Recent News hrefhttps://ir.avalotx.com/news-events-presentations/press-releases/rss /> title>Avalo Therapeutics, Inc. (AVTX)/title> link relcanonical hrefhttps://ir.avalotx.com>meta propertyog:url contenthttps://ir.avalotx.com>meta propertyog:site_name contentAvalo Therapeutics, Inc.>meta propertyog:title contentOverview>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/379/1737/social_image_resized.jpg>meta nametwitter:card contentsummary_large_image>meta propertyog:description contentAvalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.>meta namedescription contentAvalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.>script typeapplication/ld+json> {@context:http:\/\/schema.org,@type:Corporation,name:Avalo Therapeutics, Inc.,address:{@type:PostalAddress,streetAddress:1500 Liberty Ridge Drive Suite 321,addressLocality:Wayne, PA,postalCode:19087,addressCountry:},legalName:Avalo Therapeutics, Inc.,description:Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo\u2019s lead asset is AVTX-009, an anti-IL-1\u03b2 mAb, targeting inflammatory diseases.,tickerSymbol:: AVTX,url:https:\/\/ir.avalotx.com,logo:https:\/\/d1io3yog0oux5.cloudfront.net\/_c309696b5c05580c5a8a24e40542c298\/avalotx\/logo.png,image:https:\/\/d1io3yog0oux5.cloudfront.net\/_c309696b5c05580c5a8a24e40542c298\/avalotx\/db\/379\/1737\/social_image_resized.jpg,sameAs:}/script>!-- Elastic Search --> meta nameviewport contentinitial-scale1.0, widthdevice-width> link relpreconnect hrefhttps://d1io3yog0oux5.cloudfront.net> link relpreconnect hrefhttps://qmod.quotemedia.com> link hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/css/ir.stockpr.css relstylesheet typetext/css mediascreen /> link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/css/style.css> link relshortcut icon hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/favicon.ico> link relapple-touch-icon sizes180x180 hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/apple-touch-icon.png> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/favicon-32x32.png sizes32x32> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/favicon-16x16.png sizes16x16> link relmanifest hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/manifest.json> link relmask-icon hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/favicons/safari-pinned-tab.svg> meta nametheme-color content#ffffff> !-- Google GA4 code (gtag.js) -->script idgoogle-analytics srchttps://www.googletagmanager.com/gtag/js?idUA-206094115-1 async>/script>!-- Google tag (gtag.js) --> script noncewgyGjXxYUGADTf3aVhTZag> window.dataLayer window.dataLayer || ; function gtag(){dataLayer.push(arguments);} gtag(js, new Date()); gtag(config, UA-206094115-1); /script>!-- END Google GA4 code (gtag.js) --> /head>body classpg-107607 page-type-ir-overview ir > div classgeneral-wrapper> nav idheader classaffixed aria-labelMain> div idskipLinks> a href#mainContent>Skip to main content/a> a href#footer>Skip to footer/a> /div> /nav>div classclient-content needs-init idclient-header roleregion aria-labelcontains the main navigation> header rolepresentation> div classcontainer> a idlogo hrefhttps://www.avalotx.com>img srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/site-files/20250626/avalotxdev.wpenginepowered.com/wp-content/themes/avalotherapeutics/img/Avalo-logo.svg altAvalo Therapeutics, Inc. Corporate Home>/a> nav idnav> button aria-labelToggle navigation menu classnav-control>span>/span>span>/span>span>/span>/button> div classmenu-menu-container> ul idmain-nav classmenu> li idmenu-item-29 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-29> a hrefhttps://www.avalotx.com/about/>About/a> ul classsub-menu> li idmenu-item-44 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-44>a hrefhttps://www.avalotx.com/about/>Overview/a>/li> li idmenu-item-45 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-45>a hrefhttps://www.avalotx.com/about#leadership>Leadership/a> /li> li idmenu-item-46 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-46>a hrefhttps://www.avalotx.com/about#bod>Board of directors/a>/li> li idmenu-item-350 classmenu-item menu-item-type-custom menu-item-object-custom current-menu-item menu-item-350>a hrefhttps://www.avalotx.com/about/#register aria-currentpage>Register for updates/a> /li> li idmenu-item-47 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-47>a hrefhttps://www.avalotx.com/about#contact>Contact/a> /li> /ul> /li> li idmenu-item-28 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-28> a hrefhttps://www.avalotx.com/science/>Science/a> ul classsub-menu> li idmenu-item-158 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-158>a hrefhttps://www.avalotx.com/science/>Overview/a>/li> li idmenu-item-159 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-159>a hrefhttps://www.avalotx.com/science/#hs>IL-1β in HS/a>/li> li idmenu-item-160 classd-none menu-item menu-item-type-custom menu-item-object-custom menu-item-160> a hrefhttps://www.avalotx.com/science/#cppd>IL-1β in CPPD/a> /li> /ul> /li> li idmenu-item-27 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-27> a hrefhttps://www.avalotx.com/pipeline/>Pipeline/a> ul classsub-menu> li idmenu-item-162 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-162>a hrefhttps://www.avalotx.com/pipeline/#overview>Overview/a> /li> li idmenu-item-120 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-120>a hrefhttps://www.avalotx.com/pipeline/#hs>AVTX-009 for HS/a>/li> li idmenu-item-121 classd-none menu-item menu-item-type-custom menu-item-object-custom menu-item-121> a hrefhttps://www.avalotx.com/pipeline/#cppd>AVTX-009 for CPPD/a>/li> /ul> /li> li idmenu-item-26 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-26> a hrefhttps://www.avalotx.com/patients/>Patients/a> ul classsub-menu> li idmenu-item-163 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-163>a hrefhttps://www.avalotx.com/patients/#commitment>Our commitment/a>/li> li idmenu-item-164 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-164>a hrefhttps://www.avalotx.com/patients/#trials>Clinical trials/a>/li> li idmenu-item-165 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-165>a hrefhttps://www.avalotx.com/patients/#resources>Resources/a> /li> li idmenu-item-166 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-166>a hrefhttps://www.avalotx.com/patients/#therapies>Access to investigational therapies/a>/li> /ul> /li> li idmenu-item-25 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-25 menu-item-has-children current-menu-item page_item page-item-19 current_page_item current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor> a hrefhttps://ir.avalotx.com>Investors/a> ul classsub-menu investors-sub-menu> li idmenu-item-1510 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1510> a aria-currentpage hrefhttps://ir.avalotx.com/overview> Overview /a> /li> li idmenu-item-1511 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1511> a hrefhttps://ir.avalotx.com/news-events-presentations> News, events & presentations /a> /li> li idmenu-item-1512 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1512> a hrefhttps://ir.avalotx.com/analyst-coverage> Analyst coverage /a> /li> li idmenu-item-1513 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1513> a hrefhttps://ir.avalotx.com/stock-data> Stock data /a> /li> li idmenu-item-1514 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1514> a hrefhttps://ir.avalotx.com/sec-filings> SEC filings /a> /li> li idmenu-item-1515 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1515> a hrefhttps://ir.avalotx.com/corporate-governance> Corporate governance /a> /li> li idmenu-item-1516 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-1516> a hrefhttps://ir.avalotx.com/ir-resources> IR resources /a> /li> /ul> /li> li idmenu-item-24 classmenu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-24> a hrefhttps://www.avalotx.com/careers/>Careers/a> ul classsub-menu> li idmenu-item-152 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-152>a hrefhttps://www.avalotx.com/careers>Overview/a> /li> li idmenu-item-153 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-153>a hrefhttps://www.avalotx.com/careers#values>Values/a> /li> li idmenu-item-154 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-154>a hrefhttps://www.avalotx.com/careers#benefits>Benefits/a> /li> li idmenu-item-155 classmenu-item menu-item-type-custom menu-item-object-custom menu-item-155>a hrefhttps://www.avalotx.com/careers#job-openings>Job openings/a>/li> /ul> /li> /ul> /div> /nav> /div> /header>/div> div classeq-container> header classpage-banner page-hero ir-hero dark stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/389/1912/background_image_resized.jpg);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #333;> div classcontainer> div classrow justify-content-start> div classcol-lg-10> div classtext> h2 classsr-only aria-level1>Investor Relations/h2> img classone-purpose-img srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/banner/one-purpose.svg altOne purpose> img classone-purpose-img-mobile srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/banner/one-purpose-2lines.svg altOne purpose> /div> /div> /div> /div> /header> main idmainContent> section classmodule row-default row-presentation-with-image > div classcontainer> h2>Creating value through innovation and impact/h2> div classrow justify-content-center > div classcol-lg-6> div classmodule-content> div classtext-area> div classtext p data-pm-slice1 1 >Avalo is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs./p> /div> /div> /div> /div> div classcol-lg-6 px-sm-5> figure classmodule-image mb-3> img srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/482/2430/image.png alt /> /figure> a hrefhttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/367/3391/pdf/Avalo+Corporate+Presentation_December+2025.pdf classblock-link target_blank relnoopener> December 2025 Corporate Presentation /a> /div> /div> /div>/section>section classmodule latest-news row-latest-news-inline > div classcontainer> h2>Latest news/h2> div classrow> div classcol-12 col-md-6> article classmedia> div classmedia-body> p classdate> time datetime2025-11-17T16:30:00>Nov 17, 2025 4:30pm EST/time> /p> a hrefhttps://ir.avalotx.com/news-events-presentations/press-releases/detail/214/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635c4 classwrapper-link> span classlink-heading>Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)/span> /a> /div> /article> /div> div classcol-12 col-md-6> article classmedia> div classmedia-body> p classdate> time datetime2025-11-06T07:00:00>Nov 6, 2025 7:00am EST/time> /p> a hrefhttps://ir.avalotx.com/news-events-presentations/press-releases/detail/213/avalo-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-updates classwrapper-link> span classlink-heading>Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates/span> /a> /div> /article> /div> div classcol> a hrefhttps://ir.avalotx.com/news-events-presentations/press-releases classmt-5 block-link>View All News/a> /div> /div> /div>/section> div classmodule row-stock-events > div classcontainer> div classrow> div classcol-lg-6> h2>Stock information/h2> div classstock-info quote-box qtool data-qmod-tooldetailedquotetab data-qmod-params{"lang":"en","showLogo":false,"lowHigh":false,"symbol":"AVTX"}> span classloader aria-labelLoading... roleimg>/span> script typetext/template>div rv-ifdata.datatype | n/a classqmod-block-wrapper qmod-textc> h2 classqmod-heading qmod-hbg>Stock Information/h2> div classpure-g> div classpure-u-1> div classqmod-label>No Data Exists for {data.symbolstring}/div> /div> /div>/div>div rv-unlessdata.datatype | n/a> div classqmod-ui-tool> div classvalue-market-symbol heading--h3>Nasdaq: AVTX /div> div classvalue heading--h3 rv-class-negative-valuedata.pricedata.last | lt 0 rv-class-positive-valuedata.pricedata.last | gte 0>${data.pricedata.last | asQHLast tLang | numeraljs 0.00}/div> div classstock-details> div rv-qmodchangedata.pricedata.change classqmod-change> span classstock-change-text>Stock is up by /span> span classnumber>{data.pricedata.change | asQHLast tLang | numeraljs 0.00}/span> span classpercent> ({data.pricedata.changepercent | numeraljs 0.00 0.00 | postFix %})/span> /div> div>Data provided by QuoteMedia./div> div classtime-delayed>Pricing delayed by 20 minutes/div> /div> /div>/div>/script> /div>!--end stock-info--> /div> div classcol-lg-6> h2>Events/h2> a href/news-events-presentations/events classblock-link mt-3>View All Events/a> /div> /div> /div> /div>section classmodule row-default row-with-links > div classcontainer> div classrow justify-content-center > div classcol-lg-12> div classmodule-content> div classtext-area> div classtext> h2>Investor contacts/h2> p>Avalo Therapeuticsbr>a hrefmailto:IR@avalotx.com>IR@avalotx.com/a>/p>p>Meru Advisorsbr>Lauren Glaserbr>a hrefmailto:lglaser@meruadvisors.com>lglaser@meruadvisors.com/a>/p> /div> /div> /div> /div> div classcol-lg-12 mt-5> div classd-flex> /div> /div> /div> /div>/section> /main> /div> div classmodule-quick-links rolenavigation aria-labelHelpful Investor Relations pages> div classcontainer> ul> li> a href/ir-resources/contacts > span classlink-text> Contact IR /span> div classicon-container> img rolepresentation srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/icons/icon-contact.svg alt> /div> /a> /li> li> a href/rss-news-feed > span classlink-text> RSS /span> div classicon-container> img rolepresentation srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/icons/icon-rss.svg alt> /div> /a> /li> li> a href/news-events-presentations/email-alerts > span classlink-text> Email Alerts /span> div classicon-container> img rolepresentation srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/images/icons/icon-email.svg alt> /div> /a> /li> li> a href/accessibility-statement > span classlink-text> Accessibility /span> div classicon-container> span classmaterial-icons aria-hiddentrue>accessibility/span> /div> /a> /li> /ul> /div>/div>div classfooter-container idfooter> div classfooter-lines>/div> div classclient-content needs-init idclient-footer> footer> div classcontainer> div classrow footer-top wow slideInTop> div classcol-1 col-md-3 col> div classtel>610.254.4205/div> div classsocial-links> a aria-labelvisit us on LinkedIn classsocial-link in hrefhttps://www.linkedin.com/company/avalotx titleLinkedIn target_blank>span>in/span>/a> /div> /div> div classaddress col-2 col-md-9 col> 1500 Liberty Ridge Drivebr> Suite 321br> Wayne, PA 19087 /div> div classfooter-logo col-3>img srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/site-files/20250626/avalotxdev.wpenginepowered.com/wp-content/themes/avalotherapeutics/img/Avalo-logo.svg loadinglazy altAvalo>/div> /div> div classrow footer-bot wow slideInTop> div classfooter-nav> a relprivacy-policy hrefhttps://www.avalotx.com/privacy-policy/>PRIVACY POLICY/a> a hrefhttps://www.avalotx.com/disclaimer/>DISCLAIMER/a> /div> div classcopyright>©time datetime2026>2026/time> Avalo Therapeutics, Inc./div> /div> /div> /footer>/div>/div>script idcompanyVars typeapplication/json>{ asset_url: https:\/\/d1io3yog0oux5.cloudfront.net\/_c309696b5c05580c5a8a24e40542c298\/avalotx, website_base_url: https:\/\/ir.avalotx.com, ir_base_url: , hCaptchaSiteKey: 778a5748-d323-4b73-a06c-9625642de8bc, isQmod: true, site_files_path: https:\/\/d1io3yog0oux5.cloudfront.net\/_c309696b5c05580c5a8a24e40542c298\/avalotx\/files\/theme\/site-files\/20250626\/avalotxdev.wpenginepowered.com}/script>script srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/js/_js/all.js>/script> script srchttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/files/theme/js/aside/qmod/_js/all.js>/script>script idqmod srchttps://qmod.quotemedia.com/js/qmodLoader.js data-qmod-wmid93303 data-qmod-envapp data-qmod-versionv1.69.0 data-qmod-storagesession defer>/script> /div>!-- //general-wrapper -->/body>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]